NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity RFA-MH-22-190 from the NIH Guide for Grants and Contracts. This NIMH funding opportunity announcement (FOA) seeks to strengthen the evidence for effective interventions and implementation strategies that address SDoH for HIV, and ultimately improve HIV outcomes and reduce health inequities. The FOA will solicit and fund a set of implementation research projects that aim to reduce HIV inequities, with the goal to support high-impact implementation research in HIV health inequity reduction and develop a generalizable knowledge base to guide implementation of innovative strategies, inform policy, shape guidelines, and provide a model for other jurisdictions. Research projects or collaboratives will employ efficient hybrid implementation-effectiveness research designs to simultaneously advance the evidence base for effective SSDoH-encompassing interventions and test implementation strategies to accompany these interventions.
Funding Opportunity RFA-MH-22-191 from the NIH Guide for Grants and Contracts. This NIMH funding opportunity announcement (FOA) seeks to strengthen the evidence for effective interventions and implementation strategies that address SDoH for HIV, and ultimately improve HIV outcomes and reduce health inequities. The FOA will solicit and fund a set of implementation research projects that aim to reduce HIV inequities, with the goal to support high-impact implementation research in HIV health inequity reduction and develop a generalizable knowledge base to guide implementation of innovative strategies, inform policy, shape guidelines, and provide a model for other jurisdictions. Research projects or collaboratives will employ efficient hybrid implementation-effectiveness research designs to simultaneously advance the evidence base for effective SSDoH-encompassing interventions and test implementation strategies to accompany these interventions.
Notice NOT-TR-22-033 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AI-22-046 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support research on the underlying cause(s) of signs and symptoms that may persist following a Lyme disease diagnosis and antibiotic treatment.
Notice NOT-NS-23-010 from the NIH Guide for Grants and Contracts
Notice NOT-RM-22-016 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DK-22-502 from the NIH Guide for Grants and Contracts. The purpose of this Limited Competition is to extend the Chronic Renal Insufficiency Cohort (CRIC) Study by continuing to support Clinical Centers that have previously enrolled and followed study participants. The CRIC Study is a multi-center, prospective, observational cohort study of men and women with chronic kidney disease (CKD). The primary objective of this FOA is to complete follow-up of the entire cohort. Under this FOA, the Clinical Centers will complete all data collection on enrolled participants and arrange to transfer these data and all collected biosamples to the Scientific and Data Coordinating Center (SDCC) for ultimate deposition into the NIDDK Central Biorepository.
Notice NOT-PM-22-004 from the NIH Guide for Grants and Contracts
Notice NOT-HD-22-034 from the NIH Guide for Grants and Contracts
Notice NOT-HD-22-033 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-CA-22-040 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for Biomarker Characterization Centers (BCCs), one of the three scientific units of the Early Detection Research Network (EDRN). The EDRN is a national infrastructure to discover, develop, and validate biomarkers and imaging methods for early cancer detection and risk assessment. BCCs will (1) discover, develop, characterize and test new biomarkers or refine existing biomarkers, (2) develop, refine and/or standardize biomarker assays, (3) provide resources and support for the validation of biomarkers developed by the EDRN, and (4) participate in collaborative projects with other laboratories and centers.The other two scientific units of the continuing EDRN program are the Clinical Validation Centers (CVCs), which will conduct clinical research on the validation of biomarkers and will serve as resource centers for the Network by participating in collaborative biomarker validation studies with EDRN BCCs; and the Data Management and Coordinating Center (DMCC), which will support statistical and computational analyses, informatics infrastructure, study design, coordination and management of EDRN-sponsored biomarker validation studies, and the coordination of Network-wide meetings and workshops.
Funding Opportunity RFA-CA-22-039 from the NIH Guide for Grants and Contracts. The objectives of the Early Detection Research Network (EDRN; edrn.cancer.gov) are to discover, develop and validate biomarkers and imaging methods to detect early stage cancers and to translate these into clinical tests. The EDRN provides an infrastructure that is essential for this process and has successfully completed more than10 multicenter validation studies.
Notice NOT-HL-22-026 from the NIH Guide for Grants and Contracts
Notice NOT-HL-22-025 from the NIH Guide for Grants and Contracts
Notice NOT-DE-22-003 from the NIH Guide for Grants and Contracts
Notice NOT-CA-22-104 from the NIH Guide for Grants and Contracts
Notice NOT-OD-22-180 from the NIH Guide for Grants and Contracts
Notice NOT-HL-22-034 from the NIH Guide for Grants and Contracts
Notice NOT-OD-22-182 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-CA-22-038 from the NIH Guide for Grants and Contracts. Through this limited competition Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications to continue support for the Cancer Immune Monitoring and Analysis Centers Cancer Immunologic Data Center (CIMAC-CIDC) Network. The CIMAC-CIDC is a network of laboratories (CIMACs) and a bioinformatics center (CIDC) established to perform correlative studies using biospecimens from cancer immunotherapy clinical trials. Applying a comprehensive set of state-of-the-art immunoprofiling assays and bioinformatics pipelines, the CIMAC studies encompass genomics, transcriptomics, proteomics, microbiomes, and phenotyping analyses of tumor, tumor microenvironment, blood, stool, and other types of biospecimens. The ultimate goal of the CIMAC-CIDC Network is to identify biomarkers of response, resistance, and adverse events to optimize immunotherapy approaches for patients with cancer. CIMACs work with clinical trial teams and CIDC on correlative studies examining the association of biomarker data from the assays with clinical data from the trials.